Background. Anemia during pregnancy is commonly caused by iron deficiency and can have severe consequences for both the mother and the developing fetus. The aim of this retrospective study was to assess the safety and efficacy of intravenous ferric carboxymaltose (FCM) in pregnant women. Methods. All women treated with FCM for anemia during pregnancy between 2010 and 2012 at our institution were included. A matched control group was selected, including women who either were nonanemic or had anemia but were not considered for intravenous iron. Main outcome measures were maternal safety and pregnancy outcomes. Results. The study included 128 patients (FCM: 64; control: 64). Median FCM dose was 1000 mg and median gestational age at the time of first treatment was 34 weeks and 6 days. Median Hb increased from 8.4 g/dL (interquartile range 7.7; 8.9 g/dL) at the first FCM administration to 10.7 g/dL (9.8; 11.5 g/dL; n = 46 with available Hb at delivery) at the time of delivery, achieving levels similar to those in the control group (10.8 g/dL [9.8; 11.8 g/dL; n = 48]). No treatment-related adverse events were reported and no statistically significant differences in pregnancy outcomes were observed between groups. Conclusions. Within the limitations of this case control study, FCM was a safe and efficient treatment of anemia during pregnancy.
展开▼
机译：背景。怀孕期间的贫血通常是由铁缺乏引起的，可能对母亲和发育中的胎儿均造成严重后果。这项回顾性研究的目的是评估孕妇静脉注射羧甲基麦芽糖铁（FCM）的安全性和有效性。方法。在我们机构中，纳入了2010年至2012年期间接受FCM妊娠期贫血治疗的所有妇女。选择了一个匹配的对照组，包括非贫血或贫血但不考虑静脉注射铁剂的妇女。主要结局指标是孕产妇安全和怀孕结局。结果。该研究包括128名患者（FCM：64；对照组：64）。 FCM中位剂量为1000μmg，初次治疗时的中位胎龄为34周和6天。初次FCM给药时，中位数Hb从8.4μg/ dL（四分位间距7.7;8.9μg/ dL）增加到10.7μg/ dL（9.8;11.5μg/ dL； n = 46，有可用Hb） ，达到与对照组相似的水平（10.8μg/ dL [9.8；11.8μg/ dL； n = 48]）。没有报道与治疗有关的不良事件，两组之间的妊娠结局也没有统计学上的显着差异。结论。在该病例对照研究的范围内，FCM是一种安全有效的妊娠期贫血治疗方法。
展开▼
